Article Text

Download PDFPDF

Herbal medicines for asthma: a systematic review
  1. A Huntley,
  2. E Ernst
  1. Department of Complementary Medicine, School of Postgraduate Medicine and Health Studies, University of Exeter, Exeter EX2 4NT, UK
  1. Dr A HuntleyA.Huntley{at}


BACKGROUND Asthma is one of the most common chronic diseases in modern society and there is increasing evidence to suggest that its incidence and severity are increasing. There is a high prevalence of usage of complementary medicine for asthma. Herbal preparations have been cited as the third most popular complementary treatment modality by British asthma sufferers. This study was undertaken to determine if there is any evidence for the clinical efficacy of herbal preparations for the treatment of asthma symptoms.

METHODS Four independent literature searches were performed on Medline, Pubmed, Cochrane Library, and Embase. Only randomised clinical trials were included. There were no restrictions on the language of publication. The data were extracted in a standardised, predefined manner and assessed critically.

RESULTS Seventeen randomised clinical trials were found, six of which concerned the use of traditional Chinese herbal medicine and eight described traditional Indian medicine, of which five investigatedTylophora indica. Three other randomised trials tested a Japanese Kampo medicine, marihuana, and dried ivy leaf extract. Nine of the 17 trials reported a clinically relevant improvement in lung function and/or symptom scores.

CONCLUSIONS No definitive evidence for any of the herbal preparations emerged. Considering the popularity of herbal medicine with asthma patients, there is urgent need for stringently designed clinically relevant randomised clinical trials for herbal preparations in the treatment of asthma.

  • asthma
  • herbal medicine

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A survey by the National Asthma Campaign found that 60% of people with moderate asthma and 70% with severe asthma have used complementary and alternative medicine to treat their condition.1 Herbal medicine is the third most popular choice of both adults (11%) and children (6%) suffering from asthma.1

The historical importance of herbal medicine in the treatment of asthma is indisputable. Four of the five classes of drugs currently used to treat asthma—namely, β2 agonists, anticholinergics, methylxanthines and cromones—have origins in herbal treatments going back at least 5000 years.2

There is a large archive of information on herbal medicine from many cultures for the treatment of asthma. However, a significant proportion of these reports is not based on adequately designed trials. This review provides a critical analysis of herbal medicinal products used in the treatment of asthma symptoms that have been the subject of randomised clinical trials.


Computerised literature searches were performed to identify all published articles on the subject. The following databases were used: Medline, Pubmed, Cochrane Library, and Embase, all from their inception to December 1999. Search terms used were “asthma”, “herb*”, “Ayurvedic”, and “traditional Chinese medicine”, as well as any individual herb name cited in the asthma literature. In addition, other researchers in this field were asked for further papers and our own files were searched. The bibliographies of all papers thus located were searched for further relevant articles. Only randomised clinical trials (parallel and crossover) were included. There were no restrictions regarding publication language. All articles were read in full and data extracted in a predefined fashion by the first author. All trials were rated according to methodological rigour using the Jadad score (table1).3

Table 1

Scoring system to measure the likelihood of bias (Jadad3)

Asthmatic subjects were preferably defined by ATS criteria. If this was not possible they were defined as those who had reversible airway constriction. Any studies involving experimentally induced asthma or patients suffering from other medical conditions in addition to their asthma were excluded. The outcome measures considered were lung function parameters, symptom diaries, medication usage, and asthma events (unscheduled visits to doctors, antibiotics, prednisolone, or days missed from school/work). Immunological studies were not included. This paper concentrated on the lung function tests, forced expiratory volume in one second (FEV1), and airway resistance (Raw). Only a change in lung function of 15% or more was considered clinically relevant.


Seventeen randomised clinical trials of herbal preparations for the treatment of asthma were found. Six of the trials involved the use of traditional Chinese herbal medicine and eight investigated traditional Indian preparations, five of which described the use ofTylophora indica. One trial related to a traditional Japanese (Kampo) herbal preparation, TJ-96. Two further trials involved the use of marihuana and dried ivy extract.

The overall methodological quality of the trials was poor. Five of the trials included both children and adults (three papers did not state the age or age range of the participants). In none of the studies did the investigators perform a sample size calculation. Only one paper explained the method of randomisation. Dropouts and withdrawals were described in just two papers. Only nine of the trials were double blind. Thus, 14 of the 17 trials scored 3 or less of a maximum of 5 on the Jadad score.3


These studies are listed in table 2. Interpretation of the validity of trials with Chinese herbal medicines is quite difficult because of various confounding factors. The theories behind the causes of asthma and the classification of asthma into heat and cold type make representation of their results problematic. Although adverse effects were described in two of the studies, no dropouts or withdrawals were mentioned in any of the six trials. Moreover, none of the trials was blinded and no explicit description of the randomisation methods was provided. Thus, all six trials with Chinese herbal medicine had a score of 1 on the Jadad scale.

Table 2

Chinese traditional medicine and asthma

Ginkgo biloba

Concentrated ginkgo leaf liquor (15 g thrice daily) was used by Li and co-workers to treat 61 asthmatic patients aged 13–48 years.4 FEV1 was significantly increased (10%) in the treatment group at four weeks and reached a clinically relevant improvement (15%) at eight weeks (p<0.05). This increase was significantly greater than placebo (p<0.05). The authors suggest that the ginkgolides in the extract act as anti-inflammatory agents and reduce airway hyperresponsiveness and bronchospasm.

Ligusticum wallichii (L wallichii)

Shao et al 5 performed a randomised controlled trial of L wallichii(10 ml thrice daily) in 150 adult patients with moderate or severe asthma. FEV1 was significantly increased in theL wallichii group compared with baseline after one month, although only by 13% (p<0.01). Subjective symptoms were reported to improve with treatment but no details were given. No significant changes were seen in the control group. Parallel studies on guinea pigs in the same paper showed L wallichiito relax tracheal smooth muscle and decrease levels of thromboxane B2.

Strengthening body resistance method (SBR)

The effect of the SBR method (20 ml thrice daily) on 117 adult asthmatics was evaluated by Xu and co-workers.6FEV1 showed a 11% increase in the test group (p<0.05) compared with baseline over a two week period. There were no significant changes in the control group. The SBR herbal decoctions in this study contained mahuang (Ephedra sinica) so the effects of this treatment were at least partially due to a bronchodilator mechanism.

Reinforcing kidney and invigorating spleen principle (RKISP)

In a second study by Xu et al the effect of RKISP in conjunction with conventional steroid treatment was investigated in 41 severe asthmatic adults in a 4–6 month study.7 FEV1 was significantly increased compared with baseline in both the treatment (15%) and control (steroid treatment alone) (11%) groups (p<0.05). The authors suggest that the RKISP treatment increased the activity of suppressor T cells, decreasing the production of IgE. They conclude that RKISP produces additional benefit to steroid treatment.

Invigorating kidney for preventing asthma (IKPA) tablets

Xu and co-workers also investigated the prevention and treatment of seasonal asthma in 57 patients aged 15-45 years with IKPA tablets (five thrice daily) and beclomethasone dipropionate (800 μg daily).8 The FEV1 of both groups improved significantly over the three month trial period (p<0.001). The test group improved by 30% which was significantly higher than the 17% improvement seen in the control group (p<0.05). The authors suggest an anti-inflammatory, anti-hyperresponsive mode of action.

Wenyang Tonglulo mixture (WTM)

In a study by Zou et al WTM (30 ml twice daily) containing roasted mahuang was compared with oral salbutamol and inhaled beclomethasone in 68 adult asthmatic patients.9 Both groups improved throughout the eight week study. In the WTM group FEV1 improved by 30% (p<0.01) and in the control group by 16% (p<0.05) over the baseline values. The improvement in the WTM group was significantly greater than in the control group (p<0.05).


These are listed in table 3.

Table 3

Traditional Indian medicine and asthma

Picrorrhiza kurroa (P kurroa)

P kurroa is a small herb with tuberous roots that is used in Ayurvedic medicine for the treatment of various conditions including lung diseases such as asthma and bronchitis.2

In a randomised, crossover, double blind trial Doshiet al 10 usedP kurroa to treat 72 patients aged 14–60 years suffering from bronchial asthma over a 14 week period. Patients were given either P kurroa root powder (300 mg thrice daily) or an identical placebo in a three arm study (table 3). The main outcome parameters were lung function tests including FEV1 and daily diary symptom scores. There was no significant change in any of the parameters measured.

Solanum xanthocarpum/trilobatum

S xanthocarpum andS trilobatum as a powder of the whole dried plant or decoction are widely used to treat respiratory disorders by practitioners of the Sidda system of medicine in Southern India.

Sixty adult patients with bronchial asthma were randomised in a four-arm study (table 3).11 Lung function tests were performed before and two hours after drug administration. FEV1 was significantly increased above baseline levels in all groups (p<0.01). S xanthocarpum andS trilobatum increased FEV1 by 65% and 67%, respectively, at two hours but this effect was less than with conventional drugs. Subjective relief was reported after one hour and this effect lasted 6–8 hours. The authors suggest that the mechanism may involve bronchodilation, reduction of bronchial mucosal oedema, and/or reduction of airway secretions.

Boswellia serrata (B serrata)

The gum resin of B serrata is known in the Indian Ayurvedic system of medicine as Salai guggal and contains boswellic acids which have been shown to inhibit leukotriene biosynthesis.12

In a six week, double blind, randomised clinical trial of 80 adult patients with bronchial asthma Gupta and co-workers compared the effect of B serrata gum resin with placebo (lactose).13 The authors reported a significant increase in FEV1 in the B serrata group compared with placebo (p<0.0001). However, the data were presented in such a way that a percentage increase could not be calculated.

Tylophora indica (T indica)

T indica is a plant indigenous to India and reputed to be able to provide relief to patients with bronchial asthma. Five randomised clinical trials have been published on the use of T indica in the treatment of asthmatic symptoms.14-18 A substantial amount of work was carried out on T indica in asthma by Shivpuri and co-workers in the late 1960s and early 1970s including three randomised clinical trials.14-16

The first was a double blind, crossover study in 110 patients ageed 10–44+ years with bronchial asthma who ate one T indica leaf daily.14 At the end of one week 62% of the T indica group had complete to moderate relief of symptoms compared with 28% in the placebo (spinach) group. After crossover, at the end of week 1, 50% of theT indica group had improved compared with 11% of the placebo group. At 12 weeks the improvements in the two groups were 16% and 0%, respectively. No statistical analysis was performed.

The second trial reported by this group involved the use of an alcoholic tincture of T indica.15 In this study 195 patients (no ages given) with bronchial asthma were recruited into a double blind, crossover trial. After one week 56.3% of patients in theT indica group had complete to moderate improvement in symptoms compared with 31.6% in the placebo group. After the crossover 34.2% had improved with T indica and 13.5% with placebo (both statistically significant, p<0.01). After 12 weeks the results were 14.8% and 7.2%, respectively (p<0.2).

In the third double blind trial by the same research group 123 patients (no ages given) with bronchial asthma were treated with alkaloids extracted from T indica.16 The percentage of patients in whom FEV1 improved by more than 15% was significantly higher in the treated group than in the placebo group at one, two, four, eight and 12 weeks, peaking at four weeks (p<0.01). In addition, symptom scores and medication usage were also significantly improved in the test group compared with the placebo group at all time points, both being greatest at one week (p<0.05 and p<0.01, respectively).

In the study by Thiruvengadam et al 30 patients (no ages given) with bronchial asthma were enrolled into a four-arm, double blind, randomised clinical trial for 16 days. DriedT indica in capsules was compared with standard drugs and a placebo (table 3).17 The main outcome measures were lung function testing and symptom scores. Nocturnal dyspnoea was the only parameter that significantly improved withT indica compared with placebo (p<0.01).

Gupta and co-workers performed a double blind study of 135 bronchial asthma patients aged 14-60 years in whom powdered T indica was compared with placebo over six days with a follow up of two weeks.18 The authors found no statistically significant change in symptom score or lung function parameters with either T indica or the placebo and no differences were seen between the groups.

From these five trials the efficacy of T indica in the treatment of asthma symptoms is thus inconclusive.


These are listed in table 4.

Table 4

Other herbal treatments and asthma

Tsumura saiboku-to (TJ-96)

TJ-96 is the one of the most popular and best studied anti-asthmatic Kampo herbal medicines and is used both in Japan and China.2 It is a combination of two herbal preparations containing 10 herbs19 and has been used in China for steroid dependent asthma resulting in a steroid sparing effect. Despite its intensive use, there is only one randomised clinical trial in the literature from Japan.20 This 12 week study involved 112 adults with steroid dependent bronchial asthma. The main outcome measures were pulmonary function tests and asthma attacks and symptom scores calculated from symptom diaries. Unfortunately no results of the pulmonary function tests were reported and there was no description of dropout or withdrawal rates. Symptomatic improvement and patient perceptions were reported to be significantly better in the treatment group than in the control group (both p<0.01).


Marihuana was used for the treatment of asthma in the last century.21 The effects of its principal psychoactive ingredient (Δ9-tetrahydrocannabinol, THC) on pulmonary function have been investigated in normal healthy subjects.22 ,23 Only one randomised clinical trial with marihuana appears in the literature concerning its use (THC % predetermined by gas liquid chromatography) in 10 adult patients with bronchial asthma.24 Airway resistance (Raw) decreased compared with placebo and baseline after smoking the 2% THC preparation for approximately two hours, but the difference was not significant. Raw was significantly reduced by 10–13% (p<0.05) compared with placebo 1–4 hours after ingesting the 2% THC capsule. The authors suggest that the significant decrease in airway resistance (and increase in conductance) indicate that THC has a systematically active bronchodilator effect in asthmatic subjects.


In a double blind, crossover, randomised clinical trial dried ivy extract (∼35 mg) was investigated in the treatment of bronchial asthma in 24 children over three days.25 Although there was no significant improvement in FEV1, there was a significant decrease in Raw (23.6%) compared with placebo (p=0.0361). The authors suggest that ivy extract may work in a secretolytic and bronchospasmolytic manner.


Seventeen randomised clinical trials on the use of herbal medicinal products in the treatment of asthma were found in the literature. Most had significant methodological flaws and the majority were not conducted with products of standardised quality.

Trials with Ginkgo liquor,4 IKPA tablets,8WTM,9 and dried ivy extract25 produced clinically relevant improvements in lung function, significantly better than placebo or control treatment. Four of the trials withT indica 14-17 and the TJ-96 study20 resulted in a significant improvement in asthma symptoms. L wallichii,5 SBR and RKISP decoctions,6-7 P kurroa,10 Solanumsp,11 one trial with T indica,18 and marihuana24 did not produce any clinically relevant or statistically significant improvement in lung function or asthma symptoms compared with the control. Two trials, one with T indica 16 and the other with B serrata,13 reported a clinically significant improvement in FEV1 but the data were presented in such a way that the percentage change could not be calculated.

There is no fully convincing evidence for any of the herbal preparations described in this paper. Lack of blinding, description of adverse effects, and dropout/withdrawal rates were frequent limitations. Outcome measures were variable and, in several cases, of doubtful relevance. Although some trials yielded positive results, their flaws mean that further meticulous investigations are required before positive recommendations can be made.

None of the herbal medicinal products discussed here are likely to be free from adverse effects or interactions with prescribed drugs. For example, it is known that Ginkgo biloba, which is generally considered as one of the safest herbal medicinal products on the market, has a list of adverse reactions ranging from headaches and nausea to bleeding and seizure.26 Ginkgo also has potential interactions with anticoagulant and antiplatelet medicines because of its effect on platelet activating factor.26 Uncertainty therefore pertains as to the efficacy and safety of these products and it is not possible to conduct adequate risk-benefit assessments.

It is concluded that herbal medicinal products, even though in prevalent use, are of uncertain value in the treatment of asthma. For some there are promising data which warrant further investigation.


Alyson Huntley is supported by Boots the Chemists.